
- Vol 39, Issue 12
Dementia in the News
What's the latest in dementia?
SPECIAL REPORT: DEMENTIA
Research Identifies Promising Treatment for Alzheimer Disease, Other Cognitive Disorders
Erin O’Brien
Intranasal (IN) administration of an oxytocin derivative to the brain may be an effective treatment for
Leveraging previous research suggesting that introducing cell-penetrating peptides (CPPs) and a penetration-accelerating sequence (PAS) via structural modifications can benefit the nose-to-brain delivery pathway, the investigators created the oxytocin derivative PAS-CPPs-oxytocin. Their aim was to see if IN administration of this oxytocin derivative would help improve cognitive function in mice similarly to the more invasive intracerebroventricular (ICV) administration method.1
“We have previously shown that oxytocin reverses amyloid-β peptide (25-35) (Aβ25-35)-induced impairment of synaptic plasticity in rodents,” said corresponding author Jun-Ichiro Oka, PhD, in a press release. “We wanted to see if PAS-CPPs-oxytocin could be delivered more efficiently to the mouse brain for clinical application, and if it improved cognitive functional behavior in mice.”2
The investigators conducted Y-maze and Morris water maze (MWM) tests and found that ICV administration of oxytocin showed memory-improving effects on the Aβ25–35-induced amnesia in both tests, while IN administration of the oxytocin derivative showed memory-improving effects in the Y-maze test. The investigators also found evidence that, following its IN administration, the fluorescein isothiocyanate-labeled oxytocin derivative was distributed throughout the brain.1
“My team is the first to show that the oxytocin derivative can improve the Aβ25-35-induced memory impairment in mice,” Oka said in a press release. “This suggests that oxytocin may help reduce the cognitive decline we see in Alzheimer disease.”2
Oka, professor emeritus from Tokyo University of Science, further clarified that these findings are clinically useful because “the oxytocin derivative enters the brain more efficiently. Furthermore, since IN delivery is a noninvasive procedure, this modified version of the hormone could potentially be a clinically viable treatment for Alzheimer disease.”2
References
1. Takahashi J, Ueta Y, Yamada D, et al.
2. Novel derivative of “love hormone” oxytocin improves cognition impairment in Alzheimer’s. News release. Tokyo University of Science. October 24, 2022. Accessed November 4, 2022.
Nonaffective Psychosis May Represent Modifiable Risk Factor for Dementia
Leah Kuntz
Individuals with nonaffective psychotic disorders are 2.5 times more likely than those without a nonaffective psychotic disorder to eventually develop dementia, representing a new avenue of modifiable risk, new research data show.1
In the first high-quality systematic review looking at a range of
Despite speculating that antipsychotics may have a role in the development of dementia, the investigators only found 2 studies exploring this link. Moreover, those studies showed mixed results. One found a protective effect; the other found an increased risk associated with second-generation antipsychotics but a protective effect for first-generation
“Cognitive impairment and hallucinations can be symptoms of both dementia and psychotic disorders, so it is possible there could be a link between the 2 illnesses. This impairment could also limit people’s cognitive reserve, and increase their vulnerability to dementia symptoms,” said lead author Sara El Miniawi, MSc, of University College London in England.2
Regardless of the age at which an individual first develops a mental illness, those with psychotic disorders are at a higher risk of dementia later in life. Additionally, individuals with a psychotic disorder tend to be younger than average at dementia diagnosis, as young as their 60s.
Previous research indicated that 40% of dementia cases could be prevented or delayed by targeting risk factors across the life span. This study’s findings added to the list of modifiable risk factors for
“People with psychotic disorders are more likely to have other health conditions such as cardiovascular disease or obesity, which can increase the risk of dementia, while they are also more likely to have a poor diet, smoke, or use drugs, which may harm their health in ways that could increase their likelihood of developing dementia,” said Vasiliki Orgeta, PhD, an associate professor at the Division of Psychiatry, Faculty of Brain Sciences, at University College London.2
The investigators were not able to determine if effective treatment for psychotic disorders could mitigate the dementia risk, or if antipsychotic medication could be a factor, as there was limited and conflicting evidence.
References
1. El Miniawi S, Orgeta V, Stafford J.
2. Schizophrenia may increase dementia risk by 2.5 times. UCL News. October 6, 2022. Accessed November 2, 2022.
Articles in this issue
almost 3 years ago
Current Treatments for Cannabis Use Disorderalmost 3 years ago
The Importance of Cherishing the Older Adults in Your Lifealmost 3 years ago
Beyond Counting Sheep: Helping Patients With Insomniaalmost 3 years ago
Eight Best Practices for Medical Malpractice Defensealmost 3 years ago
Psychopharmacology Conference Offers New Research, Prescribing Tipsalmost 3 years ago
Use of Antipsychotics: Risks of Tardive Dyskinesiaalmost 3 years ago
On Transiencealmost 3 years ago
Beyond “Bad Behavior”: ADHD in Clinical PracticeNewsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.